Phase 1 Clinical Trial Is Assessing Cantrixil in Ovarian Cancer Patients Who Are Resistant to Chemo

Phase 1 Clinical Trial Is Assessing Cantrixil in Ovarian Cancer Patients Who Are Resistant to Chemo
Three Australian and two American cancer centers are spearheading the first clinical trial of Cantrixil, Novogen’s therapy to restore ovarian cancer patients’ sensitivity to chemotherapy. Associate Professor Jim Coward, an oncologist at Icon Cancer Care in South Brisbane, is directing the trial. In addition to Icon, the Australian trial locations are the Flinders Medical Center and Westmead Hospital

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. simon ropner says:

    Thanks.

    My sister (age 57) was diagnosed with stage 3c Ovarian Cancer in May 2015.
    She underwent surgery for de bulking and then received a fairly intensive of combination therapy (paclitaxol and carboplatin). Following this she received the maximum allowable course of Avastin. There has been no recurrence so far, but her CA125 levels are now moving up. Please can you pass on details of how she might gain access to the course as described, and i will pass the details on to her ? With many thanks and kind wishes Simon Ropner

Leave a Comment

Your email address will not be published. Required fields are marked *